Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 14:6:20.
doi: 10.1186/s40364-018-0135-x. eCollection 2018.

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy

Roberto J Arai  1 , Vanessa Petry  1 , Paulo M Hoff  1 , Max S Mano  1
Affiliations

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy

Roberto J Arai et al. Biomark Res. .

Abstract

Metronomic therapy has been gaining importance in the neoadjuvant setting of breast cancer treatment. Its clinical benefits may involve antiangiogenic machinery. Cancer cells induce angiogenesis to support tumor growth by secreting factors, such as vascular endothelial growth factor (VEGF). In breast cancer, Trastuzumab (TZM) based treatment is of key importance and is believed to reduce diameter and volume of blood vessels as well as vascular permeability. Here in we investigated serum levels of angiogenic factors VEGF and MCSF in patients receiving metronomic neoadjuvant therapy with or without TZM. We observed in HER2+ cohort stable levels of MCSF through treatment, whereas VEGF trend was of decreasing levels. In HER2- cohort we observed increasing levels of MCSF and VEGF trend. Overall, HER2+ patients had better pathological response to treatment. These findings suggest that angiogenic pathway may be involved in TZM anti-tumoral effect in the neoadjuvant setting.

Keywords: Angiogenesis; Biomarker; Breast cancer; Metronomic chemotherapy; Neoadjuvant.

PubMed Disclaimer

Conflict of interest statement

This work has been carried out in accordance with The Code of Ethics of the World Medical Association, Declaration of Helsinki, and Good Clinical Practice. This work was approved by the Ethics Committee of the Medical School of Medicine, University of Sao Paulo. The informed consent form was obtained accordingly to the current local and international legislation and standards. All patients consent to participate in this study.All patients included in this study consent to publish results. All data were anonymized as to protect individual identity as per Good Clinical Practice.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Table (a) Two-way scatter plots of VEGF serum levels (n = 96) in HER2+ patients and (b) HER2- patients (n = 108). Trend line along with R2 values is shown for each graph
Fig. 2
Fig. 2
Table (a) Two-way scatter plots of MCSF serum levels in HER2+ patients (n = 96) and (b) HER2- patients (n = 108). Trend line along with R2 values is shown for each graph
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Cantor RI, Biermann WA, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer. 1994;73(2):362–9. - PubMed
    1. Danforth DN, Jr, Lippman ME, McDonald H, Bader J, Egan E, Lampert M, et al. Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer. Am Surg. 1990;56(1):6–11. - PubMed
    1. Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol. 2006;24(22):3623–3628. doi: 10.1200/JCO.2005.04.5773. - DOI - PubMed
    1. Dellapasqua S, Mazza M, Rosa D, Ghisini R, Scarano E, Torrisi R, et al. Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. Breast. 2011;20(4):319–23. - PubMed
    1. Munzone E, Colleoni M. Metronomics in the neoadjuvant and adjuvant treatment of breast cancer. Cancer Lett. 2017;400:259–266. doi: 10.1016/j.canlet.2016.12.041. - DOI - PubMed